abstract: INTRODUCTION: Acquired @entity447 is a rare @entity548 diathesis caused by auto-immune depletion of factor VIII. It is characterised by spontaneous @entity548 , which can be fatal sometimes. EXEGESIS: A 71 year-old @entity1 presents in a dysimmunitary context ( @entity309 complicates by an acquired @entity447 ) a @entity295 with a @entity3256 resistant @entity794 . At the time of the hospitalization, the @entity1 is febrile (39 degrees C). The activated partial thromboplastin time is very much increased, the level of factor VIII is lowered by 7% and the title of the inhibitor to factor VIII amounts to 140 Bethesda unities. An haematoma of the right root thigh is also noted. In that case, the concomitant presence of @entity295 makes difficult the use of immunosuppressive therapy usually recommended to decrease auto-antibody's level. For the management of the @entity295 , an adapted antibiotherapy ( @entity2176 then @entity11248 ) is organized to J1. To control @entity548 , immunoglobulins are prescribed from d12 to d16, without immediate results. Then @entity229 is introduced. We observe a very fast decrease of the anticoagulant circulating title with a neat improvement of the clinical state, allowing so to realize a draining puncture of the psoas. This invasive investigation required the use of prothrombinic complex concentrates ((Feiba) in the dose of 80 UI/kg two to three times a day). Biopsy does not show infection source. CONCLUSION: The infection delayed the prescription of immunosuppressive therapy and the surgery. Use of corticoids, following 5 days of intravenous polyvalent immunoglobulin, was the good choice. After 7 weeks of hospitalization the @entity1 has recovered a normal haemostasis results, and a good general state.

title: [Treatment of a septic XXXX with acquired @entity447 ].

entities_list: @entity3256 :: ('MESH:D008712', 'Chemical') :: ['methicillin']

entities_list: @entity295 :: ('MESH:D018805', 'Disease') :: ['septicemia']

entities_list: @entity2176 :: ('MESH:D014640', 'Chemical') :: ['vancomycin']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['haemorrhagic risk', 'bleeding', 'haemorrhagic syndrome']

entities_list: @entity447 :: ('MESH:D006467', 'Disease') :: ['haemophilia']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity794 :: ('1280', 'Species') :: ['staphylococcus aureus']

entities_list: @entity11248 :: ('MESH:D017334', 'Chemical') :: ['teicoplanin']

entities_list: @entity309 :: ('MESH:D001172', 'Disease') :: ['rheumatoid arthritis']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: BACKGROUND: Few studies have reported on the association between inflammatory markers and @entity731 by smoking status. We investigated the effect of plasma levels of @entity2002 and high-sensitive @entity1851 (hsCRP) on subclinical @entity731 stratified by smoking in a general urban population. METHODS: From @entity1 of the Suita study without a history of @entity65 , a total of 2502 subjects (805 @entity1 , median age 64  years) who underwent carotid ultrasonography were enrolled. Subjects were divided into current smokers (n  =  566) and never-smokers. Ex-smokers were not included in the study. Each group was subdivided according to the median levels of markers (plasma @entity2002 [2.99  g/L] and hsCRP [.51  mg/L]) and the smoking amounts. We compare the adjusted maximum and mean @entity121 ( @entity121 ). RESULTS: In @entity1 and @entity1 , maximum @entity121 and mean @entity121 of the high @entity2002 and high hsCRP (Fib(H)CRP(H)) with smoking were thicker than those of the low @entity2002 and low hsCRP (Fib(L)CRP(L)) without smoking, the Fib(L)CRP(L) with smoking, and the Fib(H)CRP(H) without smoking after adjusting for covariates. The Fib(L)CRP(L) with smoking had thicker IMTs than the Fib(L)CRP(L) without smoking. There was a dose-dependent smoking effect on @entity121 in @entity1 . These trends were similar in age 60, 65, and  70. CONCLUSIONS: Plasma @entity2002 and hsCRP levels were related to multivariate-adjusted @entity121 , and smoking was associated with @entity121 in @entity1 . The combination of plasma @entity2002 and hsCRP levels could be a potential marker on subclinical @entity2998 in urban @entity1 .

title: Effect of Plasma @entity2002 , High-Sensitive @entity1851 , and Cigarette Smoking on XXXX : The Suita Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'people', 'men']

entities_list: @entity2998 :: ('MESH:D002340', 'Disease') :: ['carotid atherosclerosis']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['IMT', 'intima-media thickness']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular diseases']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']

answer: @entity2998 :: (MESH:D002340,Disease) :: ['Carotid Atherosclerosis']


abstract: BACKGROUND: Various therapeutic modalities, which are available for treating @entity4891 , have not been successful every time. AIMS: To evaluate topical @entity15464 under occlusion in the treatment of @entity4891 and compare it with cryo-therapy. MATERIALS AND METHODS: 50 @entity1 with 424 @entity4891 were included in this single center, two arm, prospective, randomized, control, open study. @entity1 were allocated randomly into two groups consisting of 25 @entity1 each. Group A @entity1 having 299 @entity4891 were treated using @entity15464 gel 0.1% under occlusion while Group B @entity1 having 125 warts were treated using cryo-therapy. All the @entity1 were evaluated weekly till the clearance of all the warts and the results compared. RESULT: All the warts of 25 @entity1 of Group A that were treated using @entity15464 gel 0.1% cleared in 36.71    19.24 (55.95-17.47) days except those in one @entity1 . In Group B, warts in all except one treated by cryo-therapy cleared in 52.17    30.06 (82.23-22.11) days. There were no side effects like scar formation, @entity146 , erythema, or @entity281 with @entity15464 group while in the cryo group scar was seen in 2 @entity1 , @entity158 in 24, erythema in 10, and @entity281 in 3 @entity1 . CONCLUSION: @entity15464 gel 0.1% under occlusion is an effective, safe and easy to use treatment for @entity4891 and may help @entity75 faster than cryo-therapy.

title: Topical @entity15464 in the treatment of XXXX ; randomized comparative open trial in comparison with cryo-therapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['irritation']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['clear lesions']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'infections']

entities_list: @entity15464 :: ('MESH:C063610', 'Chemical') :: ['adapalene', 'Adapalene']

entities_list: @entity4891 :: ('MESH:D014860', 'Disease') :: ['plantar warts', 'plantar wart']

answer: @entity4891 :: (MESH:D014860,Disease) :: ['plantar warts']


abstract: BACKGROUND: Direct factor (F)Xa inhibition is an attractive method to limit @entity715 complications during percutaneous coronary intervention (PCI). OBJECTIVES: To investigate drug levels achieved, effect on coagulation markers, and preliminary efficacy and safety of several doses of @entity44912 , an intravenous, small molecule, direct, reversible @entity6236 inhibitor during PCI. @entity1 AND METHODS: @entity1 undergoing elective, native-vessel PCI (n = 175) were randomized 4 : 1 to open-label DX-9065a or heparin in one of four sequential stages. DX-9065a regimens in stages I-III were designed to achieve concentrations of > 100 ng @entity19264 , > 75 ng @entity19264 , and > 150 ng @entity19264 . Stage IV used the stage III regimen but included @entity1 recently given heparin. RESULTS: At 15 min median (minimum) DX-9065a plasma levels were 192 (176), 122 (117), 334 (221), and 429 (231) ng @entity19264 in stages I-IV, respectively. Median whole-blood international normalized ratios (INRs) were 2.6 (interquartile range 2.5, 2.7), 1.9 (1.8, 2.0), 3.2 (3.0, 4.1), and 3.8 (3.4, 4.6), and anti- @entity6236 levels were 0.36 (0.32, 0.38), 0.33 (0.26, 0.39), 0.45 (0.41, 0.51), and 0.62 (0.52, 0.65) U @entity19264 , respectively. Stage II enrollment was stopped (n = 7) after one serious @entity715 event. Ischemic and @entity548 events were rare and, in this small population, showed no clear relation to DX-9065a dose. CONCLUSIONS: Elective PCI is feasible using a direct @entity6236 inhibitor for anticoagulation. Predictable plasma drug levels can be rapidly obtained with double-bolus and infusion DX-9065a dosing. Monitoring of DX-9065a may be possible using whole-blood INR. Direct @entity6236 inhibition is a novel and potentially promising approach to anticoagulation during PCI that deserves further study.

title: Initial experience with XXXX inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombotic']

answer: @entity6236 :: (2159,Gene) :: ['factor-Xa']


abstract: Fourteen @entity1 with @entity2212 received combination chemotherapy with @entity2664 5 mg/m2 intravenously daily for 3 days, @entity2592 100 mg/m2 intravenously over 2 hours bid for 7 days and high dose @entity1667 1000 mg/day intravenously for 5 days. The @entity1 ' mean age was 52 +/- 10 (range 34-64) and @entity8487 chromosome was positive in all. Five @entity1 (35%) achieved complete remission and four @entity1 (28%) had a partial remission. Overall remission rate was 64%. The mean survival was 11.1 +/- 8.6 months (median 13) for all @entity1 , 19.4 +/- 4.0 months (median 19) for those achieving a complete remission, 12.50 +/- 5.7 months (median 14) for @entity1 with partial remission and 1.8 +/- 1.8 months (median 2) for the unresponsive @entity1 . Two of 5 unresponsive @entity1 died early after the second course of remission induction. The treatment regimen was generally well tolerated. @entity236 was observed in 9 (64%) @entity1 and 7 (50%) had febrile episodes. Non-myelosupressive @entity137 of the regimen was acceptable. @entity1209 were observed in 8 (57%) @entity1 and 3 (21%) @entity1 developed @entity1671 due to @entity2592 . These results suggest that the regimen with @entity2664 , @entity2592 and high dose @entity1667 in remission-induction of @entity2212 may be a valid option that may also improve overall prognosis.

title: Treatment of @entity2212 with @entity2664 , @entity2592 and high dose XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone']

entities_list: @entity2212 :: ('MESH:D015466', 'Disease') :: ['blastic phase chronic myelogenous leukemia']

entities_list: @entity8487 :: ('MESH:D010677', 'Disease') :: ['Philadelphia']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone']

entities_list: @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytosine arabinoside']

entities_list: @entity236 :: ('MESH:D001855', 'Disease') :: ['Marrow hypoplasia']

entities_list: @entity1209 :: ('MESH:D020250', 'Disease') :: ['Nausea and vomiting']

answer: @entity1667 :: (MESH:D008775,Chemical) :: ['methylprednisolone']


abstract: UNASSIGNED: Although physical activity (PA) improves arterial distensibility, it is unclear which type of activity is most beneficial. We aimed to examine the association of different types of PA with @entity3538 ( @entity3538 ) and the mechanisms involved. Data included 4503 Australians and Finns aged 26-45 years. Physical activity was measured by pedometers and was self-reported. @entity3538 was measured using ultrasound. Other measurements included resting heart rate (RHR), @entity410 ( @entity410 ), blood pressure, biomarkers and anthropometry. Steps/day were correlated with RHR (Australian @entity1 r=-0.10, @entity1 r=-0.14; Finnish @entity1 r=-0.15, @entity1 r=-0.11; P<0.01), @entity410 and biochemical markers, but not with @entity3538 . Self-reported vigorous leisure-time activity was more strongly correlated with RHR (Australian @entity1 r=-0.23, @entity1 r=-0.19; Finnish @entity1 r=-0.20, @entity1 r=-0.13; P<0.001) and @entity410 , and was correlated with @entity3538 (Australian @entity1 r=0.07; Finnish @entity1 r=0.07, @entity1 r=0.08; P<0.05). This relationship of vigorous leisure-time activity with @entity3538 was mediated by RHR independently of potential confounders. In summary, vigorous leisure-time PA but not total or less intensive PA was associated with arterial distensibility in young to mid-aged adults. Promotion of vigorous PA is therefore recommended among this population. RHR was a key intermediary factor explaining the relationship between vigorous PA and arterial distensibility. @entity101 Research advance online publication, 19 February 2015; doi:10.1038/hr.2015.9.

title: Vigorous physical activity and XXXX in young and mid-aged adults.

entities_list: @entity3538 :: ('MESH:D002341', 'Disease') :: ['carotid distensibility', 'CD']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['cardiorespiratory fitness', 'CRF']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['Hypertension']

answer: @entity3538 :: (MESH:D002341,Disease) :: ['carotid distensibility']


abstract: UNASSIGNED: 8575 Background: Current advances in the understanding of @entity320 biology and genetics gave a solid rationale to introduce different targeted therapies into clinical trials. In @entity1 harbouring @entity817 mutations, 60-80% objective response rate has been described after treatment with @entity817 inhibitors like @entity5457 or @entity5458 . Also, preliminary clinical experience in @entity1 with @entity320 with gene amplification or activating mutations of @entity2467 treated with @entity2213 , have shown high response rates and prolonged progression free survival. These results emphasise the importance of molecular information, even in those cases in which the diagnosis was made on small samples obtained through minimally invasive approaches. Cytology is an accurate and cost-effective tool for the diagnosis of @entity5 and in many times cytological smears are the only samples available from these @entity1 . METHODS: We studied @entity817 and @entity2467 mutations in cytological samples from 44 consecutive @entity1 with @entity320 . Diagnosis was made on fine needle aspiration in 34 cases, imprints in 6, direct eye touch in 1 and pleural and peritoneal fluid in 3. To assure tissue quality, DNA was extracted directly from Papanicolau stained smears on which cytological diagnosis was made. @entity817 and @entity2467 mutations were analysed by PCR and direct sequencing using an ABI PRISM TM 310XL. RESULTS: Our series include 25 @entity1 and 19 @entity1 with a median age of 54 years. @entity817 mutations was found in 22 @entity1 (50%): @entity8554 mutation in 19 (86,4%) and @entity16232 in 3 (13,6%). @entity2467 mutation was also studied in 18 @entity1 and was found in 1 @entity1 with @entity320 (5.6%). @entity817 status did not correlated with primary @entity320 histology, disease free survival, brain metastases rate and overall survival. CONCLUSIONS: Activating mutations in @entity817 are common in cutaneous @entity320 (50% in our series). Mutational analysis of @entity817 and @entity2467 using cytological samples from @entity1 with @entity320 is feasible and it can be used to extend the benefits of targeted therapy to those @entity1 from which biopsies are not available.

title: Feasability and reliabity of the assessment of @entity817 and XXXX mutations in cytologic samples from @entity320 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'patient', 'men']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['metastatic cancer']

entities_list: @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'metastatic melanoma', 'acral melanoma', 'mucosal or acral melanomas']

answer: @entity2467 :: (3815,Gene) :: ['c-KIT']


abstract: @entity8162 ( @entity4901 ) is a conventional chemotherapeutic agent for @entity421 . Recent study has proposed that the growth-inhibitory effect of @entity4901 was by regulation of microRNAs. @entity19953 has been proved to be a @entity5 suppressor of @entity421 , while whether it was involved in anti- @entity5 effects of @entity4901 on @entity421 has not been investigated. Thus, in this study, we aimed to explore the effects of @entity4901 on @entity421 MG63 cells by regulation of @entity19953 , as well as its underlying mechanisms. MG63 cells were treated with different concentrations of @entity4901 , and then cell viability, apoptosis and @entity19953 were respectively detected by @entity98 , flow cytometer and qRT-PCR. Next, cells were first transfected with @entity19953 inhibitor and then treated with 2  M of @entity4901 ; thereafter, cell viability, migration and apoptosis were detected. Analysis of signaling pathways were detected by western blot. Our results showed that @entity4901 significantly inhibited cell viability and promoted apoptosis and expression level of @entity19953 in a dose-dependent way (P < 0.05 or P < 0.01). Moreover, we observed that @entity4901 + @entity19953 inhibitor dramatically reversed the effects of @entity4901 on cell viability, apoptosis, and migration (P < 0.05 or P < 0.01). In addition, @entity4901 significantly decreased the levels of p/t- @entity584 (p-308 or p473), p/t- @entity3963 , and p/t-S6, while @entity4901 + @entity19953 inhibitor rescued these effects. Our results suggest @entity4901 inhibits proliferation and migration, but promotes apoptosis in @entity421 cells by up-regulation of @entity19953 . These effects may be achieved by inactivation of @entity584 / @entity3963 pathways.

title: XXXX Inhibits Proliferation and Migration and Promotes Cell Apoptosis in @entity421 Cells By Upregulation of @entity19953 .

entities_list: @entity8162 :: ('MESH:D011343', 'Chemical') :: ['Procaine']

entities_list: @entity421 :: ('MESH:D012516', 'Disease') :: ['osteosarcoma']

answer: @entity8162 :: (MESH:D011343,Chemical) :: ['Procaine']


abstract: BACKGROUND: The pathophysiology of acute @entity788 involves activation of the pancreatic proenzymes. Levels of the trypsinogen activation peptide in urine in acute @entity788 has been shown to correlate with the severity of disease. However, this peptide is unstable in urine and, because of its low molecular mass, difficult to measure. @entity16679 has a larger activation peptide which could be more suitable for analysis in serum and urine. AIMS: To study the presence of the activation peptide from @entity16679 ( @entity54840 ) in serum and urine in acute @entity788 . @entity1 : Urine and serum samples were obtained within 48 hours of admittance from 40 @entity1 with acute @entity788 . Severity was classified retrospectively according to levels of C-reactive protein and clinical course. Thirty four @entity1 with @entity490 from other causes were studied as controls. METHODS: @entity54840 was purified from @entity1 pancreatic juice. Specific antibodies were obtained and a radioimmunoassay was developed. RESULTS: Levels of @entity54840 in serum and urine in acute @entity788 correlate with the severity of the attack. @entity54840 is very stable, and urine contains only @entity54840 whereas, in serum, cross reacting @entity16679 is found together with @entity54840 . CONCLUSIONS: @entity54840 could be a valuable tool in the diagnosis and early determination of severity in acute @entity788 .

title: Activation peptide of carboxypeptidase B in serum and urine in acute XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'human', 'PATIENTS']

entities_list: @entity16679 :: ('1360', 'Gene') :: ['Procarboxypeptidase B', 'procarboxypeptidase B']

entities_list: @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

answer: @entity788 :: (MESH:D010190,Disease) :: ['pancreatitis']


abstract: BACKGROUND AND AIM: @entity2298 is a risk factor for @entity731 that is typically associated with high concentrations of adhesion molecules, impaired hemorrheology and an unfavourable low-density lipoprotein (LDL) subtype distribution. We hypothesised that some of these risk markers might be beneficially influenced by lipid-lowering therapy with @entity2993 in @entity6308 @entity1 . METHODS AND RESULTS: Nineteen patents with primary @entity2298 were given 10 mg of @entity2993 per day for four weeks. Their @entity165 , @entity412 , LDL and high-density lipoprotein @entity165 (HDL-C) levels, LDL subtype profile, hemorrheological parameters and @entity4105 , @entity67182 concentrations were measured before and at the end of @entity2993 therapy. The levels of total and LDL @entity165 respectively decreased by 25% and 24% (both p < 0.001). Furthermore, @entity165 was reduced by 8-29% in all seven LDL subfractions (density range: 1.020-1.066 g/mL) (p < 0.05). The reduction in @entity412 concentrations was of marginal significance (9%, p = 0.1), but its degree positively correlated with the reduction of small-dense LDL (r = 0.5, p < 0.025). Plasma viscosity and blood viscosity at low shear rates were respectively reduced by 2% and 16% (both p < 0.05). The effect of the treatment on the concentrations of HDL-C, fibrinogen and adhesion molecules was not significant. CONCLUSIONS: @entity2993 (10 mg/day) not only reduced the plasma concentrations of atherogenic lipoproteins but also improved the LDL-subtype profile and reduced plasma and blood viscosity in @entity1 with @entity2298 ; however, it failed to significantly lower @entity412 concentrations.

title: Effect of @entity2993 on lipid parameters, LDL subtype distribution, hemorrheological parameters and adhesion molecule concentrations in XXXX with @entity2298 .

entities_list: @entity2298 :: ('MESH:D015228', 'Disease') :: ['Hypertriglyceridemia', 'hypertriglyceridemia']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity6308 :: ('MESH:D064250', 'Disease') :: ['hypertriglyceridemic']

entities_list: @entity2993 :: ('MESH:C065179', 'Chemical') :: ['atorvastatin', 'Atorvastatin']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity67182 :: ('7412;3383', 'Gene') :: ['vascular cell adhesion molecule-1 and intercellular adhesion molecule-1']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVE: To test whether @entity1063 (NE) infusion at 0.4 microg kg(-1) @entity1009 ) adversely affects regional blood flow in the normal @entity1 circulation. DESIGN AND SETTING: Randomized cross-over experimental animal study in a university-affiliated physiology institute. SUBJECTS: Six merino ewes. INTERVENTIONS: Staged insertion of transit-time flow probes around the ascending aorta and circumflex coronary, superior mesenteric and left renal arteries. In conscious animals with chronically embedded flow probes randomization to either 6 h of placebo (saline) or drug (NE at 0.4 microg kg(-1) @entity1009 )). MEASUREMENTS AND RESULTS: Compared to placebo, NE significantly increased mean arterial pressure (84.4 vs. 103.8 mmHg), heart rate (61.0 vs. 74.6 bpm) and cardiac output (3.76 vs. 4.78 l/min). These changes were associated with an increase in coronary blood flow (24.2 vs. 37.4 ml/min) and renal blood flow (215.2 vs. 282.0 ml/min) but no change in mesenteric blood flow. The increase in renal and coronary blood flow was associated with an increase in regional conductance (regional vasodilatation), while mesenteric conductance fell (mesenteric vasoconstriction). Urine output (91+/-17 vs. 491+/-360 ml/h) and @entity1011 clearance (61+/-18 vs. 89+/-12 ml/min) increased during NE infusion. CONCLUSIONS: NE infusion does not induce vital organ ischaemia in the normal @entity1 circulation. Furthermore, it results in a significant increase in @entity8 with a concomitant improvement in urine output and @entity1011 clearance.

title: XXXX and vital organ blood flow.

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['coronary and renal blood flow']

entities_list: @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine']

entities_list: @entity1063 :: ('MESH:D009638', 'Chemical') :: ['norepinephrine']

answer: @entity1063 :: (MESH:D009638,Chemical) :: ['Norepinephrine']


abstract: PURPOSE: To evaluate parameters that may influence prognosis in @entity1 treated with preoperative radiotherapy (RT) or chemoradiation. METHODS AND MATERIALS: One hundred seventy-six @entity1 with @entity418 received preoperative radiotherapy (45 @entity1 ) or chemoradiation (131 @entity1 ). Forty-three received no surgery (NS), 32 had exploratory surgery (ES), and 101 received definitive surgery (DS). RESULTS: Five-year cause-specific survival and absolute survival rates were overall, 19% and 16%; NS group, 0% and 0%; ES group, 3% and 3%; DS group, 30% and 26%. On univariate analysis, definitive surgery (P < 0.0001), @entity5 size less than 5 cm (P < 0.0001), and chemotherapy (P = 0.0015) were significant predictors of improved cause-specific survival. Cause-specific survival was 51% for @entity5 </=3 cm (n = 33), 32% for 3.1 to 4 cm (n = 28), and 16% for 4.1 to 5 cm (n = 29). No @entity1 with a @entity5 >/=6 cm (n = 86) survived. Multivariate analysis of the DS group showed complete or partial pathologic response (P = 0.0001), chemotherapy (P = 0.0026), and overall treatment time less than 3 months (P = 0.0405) significantly predicted improved cause-specific survival. Tumor <5 cm was marginally significant (P = 0.0515). CONCLUSION: @entity1 who undergo preoperative chemoradiation and definitive surgery have improved survival.

title: Factors predictive of survival for XXXX treated with preoperative radiotherapy with or without chemotherapy followed by surgery.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity418 :: ('MESH:D004938', 'Disease') :: ['esophageal carcinoma']

answer: @entity418 :: (MESH:D004938,Disease) :: ['esophageal carcinoma']


abstract: BACKGROUND: We examined the presence of command auditory @entity1833 for suicide (CAHS) in a sample of individuals with @entity161 or @entity914 . We examined the relationship between CAHS and demographic and clinical variables. We also investigated the relationship between CAHS and suicide attempts. METHOD: 100 individuals with DSM-IV @entity161 or @entity914 hospitalized on an inpatient research unit participated. Information was gathered using the Diagnostic Interview for Genetic Studies and the Harkavy Asnis Suicide Scale. Data were gathered from 1995 to 2001. RESULTS: CAHS were frequent in this sample (22%), as were suicide attempts (33%). Eight percent of the entire sample (36% of those who experienced CAHS) made at least 1 suicide attempt in response to the @entity1833 . The presence of CAHS was not related to demographic or clinical measures assessed. The frequency of CAHS was not statistically different for suicide attempters (30%) and nonattempters (18%). However, 80% (8/10) of attempters with CAHS reported at least 1 attempt in response to CAHS. Three of 6 repeat attempters who made at least 1 suicide attempt in response to CAHS also made other attempts that were not in response to CAHS. The presence of CAHS was not associated with a history of @entity308 or substance abuse/dependence. CONCLUSION: The presence of CAHS does not directly predict suicide attempts. However, individuals who are already at risk for suicidal behavior (e.g., past attempters) may be at increased risk for a suicide attempt when experiencing CAHS.

title: Suicide attempts in @entity161 : the role of command auditory XXXX for suicide.

entities_list: @entity1833 :: ('MESH:D006212', 'Disease') :: ['hallucinations']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

entities_list: @entity914 :: ('MESH:D011618', 'Disease') :: ['schizoaffective disorder']

answer: @entity1833 :: (MESH:D006212,Disease) :: ['hallucinations']


abstract: BACKGROUND: @entity1 outcomes after open @entity1028 and @entity449 repair have been widely reported from several large, randomized, controlled trials. It is not clear whether these trial outcomes are representative of @entity1028 repair procedures performed in real-world hospital settings across the United States. This study was designed to evaluate population-based outcomes after @entity449 repair versus open @entity1028 repair using statewide inpatient databases and examine how they have helped improve our understanding of @entity1028 repair. METHODS: A systematic search of MEDLINE, EMBASE, and CINAHL databases was performed to identify articles comparing @entity449 repair and open @entity1028 repair using data from statewide inpatient databases. This search was limited to studies published in the English language after 1990, and abstracts were screened and abstracted by 2 authors. RESULTS: Our search yielded 17 studies published between 2004 and 2016 that used data from 29 different statewide inpatient databases to compare @entity449 repair versus open @entity1028 repair. These studies support the randomized, controlled trial results, including a lower mortality associated with @entity449 repair extended from the perioperative period up to 3  years after operation, as well as a higher complication rate after @entity449 repair. The evidence from statewide inpatient database analyses has also elucidated trends in procedure volume, @entity1 case mix, volume-outcome relationships, and health care disparities associated with @entity449 repair versus open @entity1028 repair. CONCLUSION: Population analyses of @entity449 repair and open @entity1028 repair using statewide inpatient databases have confirmed short- and long-term mortality outcomes obtained from large, randomized, controlled trials. Moreover, these analyses have allowed us to assess the effect of @entity449 repair adoption on population outcomes and @entity1 case mix over time.

title: Effectiveness of open versus endovascular XXXX repair in population settings: A systematic review of statewide databases.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patient', 'patient']

entities_list: @entity449 :: ('MESH:D001014', 'Disease') :: ['endovascular aortic aneurysm']

entities_list: @entity1028 :: ('MESH:D017544', 'Disease') :: ['abdominal aortic aneurysm']

answer: @entity1028 :: (MESH:D017544,Disease) :: ['abdominal aortic aneurysm']


abstract: PURPOSE: International guidelines do not provide strong recommendations on the duration and intensity of follow-up after @entity1151 ( @entity1151 ), nor on screening-programs for @entity120 ( @entity120 ). We aimed to address this gab by performing an external validation of the easy " @entity120 rule-out-criteria" based on a normal NT-proBNP level and the absence of 3 ECG characteristics. METHODS: 134 @entity1 underwent clinical follow-up 6months after @entity1151 . Predefined transthoracic echocardiographic (TTE) criteria were used to categorize @entity1 as "PH unlikely" or "PH possible/likely". The latter @entity1 underwent further (invasive) diagnostic procedures to confirm and classify the diagnosis of @entity120 . NT-proBNP and ECGs, both assessed at the day of echocardiography, were evaluated post-hoc. RESULTS: Sixty-three @entity1 (47%) scored none of the " @entity120 rule-out criteria" positive, of whom 61 had normal TTE (97%). Twenty-five @entity1 (19%) were categorized by TTE as "PH possible/likely"; of those, 6 were diagnosed with @entity120 . The sensitivity of rule-out criteria for @entity120 was 100% (95%CI 56-100%; 6/6 @entity1 identified), and for "PH possible/likely" on TTE 92% (95%CI 74-99%; 23/25 @entity1 identified): 2 asymptomatic @entity1 with estimated systolic pulmonary arterial pressure of 36mmHg and 38mmHg, respectively, who remained stable during further 2-year follow-up, were not identified. Inter-observer agreement for the adjudication of the ECG characteristics was excellent (kappa-statistic 0.97). CONCLUSIONS: In this external validation cohort, we confirmed the diagnostic accuracy and reproducibility of the " @entity120 rule-out criteria". These results provide a solid ground for future outcome trials applying this algorithm.

title: External validation of a simple non-invasive algorithm to rule out @entity120 after XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity120 :: ('MESH:D006976', 'Disease') :: ['pulmonary hypertension', 'chronic thromboembolic pulmonary hypertension', 'CTEPH']

entities_list: @entity1151 :: ('MESH:D011655', 'Disease') :: ['PE', 'acute pulmonary embolism']

answer: @entity1151 :: (MESH:D011655,Disease) :: ['acute pulmonary embolism']


abstract: @entity293 due to uropathogenic @entity526 is a common clinical problem. The innate immune system and the uroepithelium are critical in defence against @entity281 . The complement system is both part of the innate immune system and influences the interaction between epithelium and pathogen. We have therefore investigated the mechanism by which uropathogenic @entity526 activate complement and the potential for this to occur during @entity922 . The classical pathway is responsible for bacterial opsonisation when complement proteins are present at low concentrations. At higher concentrations the alternative pathway predominates but still requires the classical pathway for its initiation. In contrast the mannose binding lectin pathway is not involved. Early classical pathway components are present in the urine during @entity281 and actively contribute to bacterial opsonisation. The classical pathway could be initiated by anti-E. coli antibodies of IgG or IgM subclasses that are present in urine during @entity281 . Additionally immunoglobulin-independent mechanisms, such as direct C1q binding to bacteria, may be involved. In conclusion, uropathogenic @entity526 are readily opsonised by complement in a classical pathway dependent manner. This can occur within the urinary tract during the development of @entity922 .

title: The classical complement pathway plays a critical role in the opsonisation of uropathogenic XXXX .

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity922 :: ('MESH:D013568', 'Disease') :: ['clinical infection']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['Urinary tract infection']

entities_list: @entity526 :: ('562', 'Species') :: ['Escherichia coli', 'E. coli']

answer: @entity526 :: (562,Species) :: ['Escherichia coli']


abstract: Twenty-four out of 164 (14%) adult @entity1 with primary germ cell @entity5 of testis seen over the last 6 years at the Institute @entity5 Hospital (IRCH) of the All India Institute of Medical Sciences (AIIMS), New Delhi, were found to have cryptorchidism. Only one @entity1 had undergone correction. As a result the testes were intra-abdominal in the vast majority, and @entity1 presented late. Twenty-two @entity1 presented with stage IIb or more @entity1442 . Twelve @entity1 had @entity4797 and the others had mixed or non-seminomatous @entity5 (NSGCT), i.e. 50% each. The earlier @entity1 were managed by initial resection followed by radiation and/or chemotherapy. As experience grew the seven @entity1 who presented late were given initial chemotherapy followed by resection in those with @entity5 . The probability of overall survival was 0.65 at 36 months and, was not significantly different from survival in 114 @entity1 with @entity5 of normally descended testis. Early orchipexy facilitates the detection, but whether it reduces the incidence of @entity5 is controversial. Uncorrected cryptorchidism is now rarely seen in the West, but in India and many other developing countries @entity5 of uncorrected cryptorchid testes continue to be seen.

title: @entity5 in uncorrected cryptorchid testis at Institute XXXX Hospital, New Delhi.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Rotary Cancer', 'germ cell tumour', 'tumours', 'residual tumours']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Rotary Cancer']


abstract: UNASSIGNED: e15115 Background: A Phase III clinical trial ( NCT00321620 ) recently demonstrated that denosumab delayed time to 1(st) skeletal-related event (SRE) and subsequent SREs longer than @entity4381 (ZA), but showed no difference in either survival or disease progression between the two products. The objective of this study was to conduct an economic evaluation of denosumab compared to ZA in the treatment of bone metastases in @entity1 with @entity263 . METHODS: A Markov model was developed to assess the one-year costs and effectiveness associated with the two treatments. Transition probabilities associated with experiencing the first SRE, subsequent SREs, disease progression, and @entity204 were primarily derived from the results of the Phase-III clinical trial, and, supplemented with published literature. Costs associated with progression, SREs, adverse events, and @entity204 were obtained from the literature and estimated as paid amounts in 2010 dollars. The model results include theincremental cost per SRE avoided. One-way sensitivity analyses were performed to test the robustness of the model. RESULTS: The total costs incurred over one year were estimated at  37,854 for denosumab and  30,499 for ZA, with an incrementally higher cost of  7,355 for denosumab. The estimated number of SREs during the one-year period was 0.56 for denosumab and 0.67 for ZA, where the denosumab @entity1 had 0.11 fewer SREs. The incremental cost per SRE avoided with the use of denosumab was  66,864. The one-way sensitivity analysis indicated that the cost per SRE avoided was driven by the differences in the drug costs, risk of progression, and risk of first SRE. CONCLUSIONS: Although denosumab was shown to be more effective than @entity4381 in delaying SREs in the recently completed Phase III trial, its use is associated with high costs. Health plans need to carefully consider these high costs prior to making decisions regarding formulary inclusion and reimbursement.

title: Economic evaluation of denosumab compared with @entity4381 in XXXX with @entity263 with bone metastases.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity4381 :: ('MESH:C088658', 'Chemical') :: ['zoledronic acid']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['hormone-refractory prostate cancer']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: The differential role of the cerebellar cortex and nuclei has rarely been addressed in @entity1 lesion and functional brain imaging studies. One important reason is the difficulty of defining the localization of the cerebellar nuclei and extent of possible lesions based on CT or MR scans. The present MRI investigation was specifically designed to study the anatomy of the @entity76 . In both basal ganglia and cerebellar nuclei of healthy @entity1 subjects the amount of @entity68 is high compared to the rest of the brain. Clusters of @entity68 are paramagnetic and, therefore, tend to cause local inhomogenities in a magnetic field. The @entity68 -induced susceptibility artefacts were used to visualize the cerebellar nuclei as hypointensities on MR images. A three-dimensional atlas of the dentate (D), interposed (I), and fastigial (F) nuclei is presented in standard proportional stereotaxic space coordinates based on findings in a healthy 26-year-old female. A three-dimensional axial volume of the cerebellum was acquired using a T1-weighted fast low-angle shot (FLASH) sequence on a Siemens Sonata 1.5 Tesla MR. To increase the signal to noise ratio the sequence was acquired 5 times and averaged. Each volume was registered, resampled to 1.00 x 1.00 x 1.00-mm3 voxel size and spatially normalized into a standard proportional stereotaxic space (the MNI-space) using SPM99. Localization of cerebellar nuclei were confirmed by comparison with postmortem MRI and histological microsections of another brain.

title: MRI atlas of the XXXX cerebellar nuclei.

entities_list: @entity76 :: ('MESH:D002526', 'Disease') :: ['deep cerebellar nuclei']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: Home-based therapy with ready-to-use therapeutic food (RUTF) for the treatment of @entity3147 has better outcomes in the research setting than standard therapy. This study examined outcomes of malnourished @entity1 aged 6-60 months enrolled in operational home-based therapy with RUTF. @entity1 enrolled in 12 rural centres in southern Malawi were diagnosed with moderate or severe @entity3147 according to the World Health Organization guidelines. They were treated with 733 kJ kg(-1) day(-1) of RUTF and followed fortnightly for up to 8 weeks. Staff at each centre followed one of three models: medical professionals administered treatment (5 centres), @entity1 were referred by medical professionals and treated by community health aids (4 centres), or community health aids administered treatment (3 centres). The primary outcome of the study was clinical status, defined as recovered, failed, died or dropped out. @entity2357 modelling was conducted to determine what aspects of the centre (formal training of staff, location along a main road) contributed to the outcome. Of 2131 severely malnourished @entity1 and 806 moderately malnourished, 89% and 85% recovered, respectively. Thirty-four (4%) of the moderately malnourished @entity1 failed, with 20 (2%) deaths, and 61 (3%) of the severely malnourished @entity1 failed, with 29 (1%) deaths. Centre location along a road was associated with a poor outcome. Outcomes for severely malnourished @entity1 were acceptable with respect to both the Sphere guidelines and the Prudhon case fatality index. Home-based therapy with RUTF yields acceptable results without requiring formally medically trained personnel; further implementation in comparable settings should be considered.

title: A large-scale operational study of home-based therapy with ready-to-use therapeutic food in childhood XXXX in Malawi.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'Children']

entities_list: @entity3147 :: ('MESH:D044342', 'Disease') :: ['malnutrition']

entities_list: @entity2357 :: ('MESH:C537770', 'Disease') :: ['Regression']

answer: @entity3147 :: (MESH:D044342,Disease) :: ['malnutrition']


abstract: Purpose: We evaluated the role of adjuvant therapy in stage IIIA endometrioid @entity420 @entity1 who underwent surgery followed by radiotherapy (RT) alone or chemoradiotherapy (CTRT) according to risk group. Materials and Methods: A multicenter retrospective study was conducted including @entity1 with surgical stage IIIA @entity1204 treated by radical surgery and adjuvant RT or CTRT. @entity66 ( @entity66 ) and @entity1349 ( @entity1349 ) were analyzed. Results: Ninety-three @entity1 with stage IIIA disease were identified. Nineteen @entity1 (20.4%) experienced recurrence, mostly distant @entity3 (17.2%). Combined CTRT did not affect @entity66 (74.1% vs. 82.4%, p=0.130) or @entity1349 (96.3% vs. 91.9%, p=0.262) in stage IIIA disease compared with RT alone. @entity1 with age>= 60, grade G2/3, and lymphovascular space involvement had a significantly worse @entity66 and those variables were defined as risk factors. The high risk group showed a significant reduction in 5-year @entity66 (>= 2 risk factors) (49.0% vs. 88.0%, P<0.001) compared with the low risk group (< 2). Multivariate analysis confirmed that more than one risk factor was the only predictor of worse @entity66 (HR, 5.45; 95% CI, 2.12-13.98; p<0.001). Of @entity1 with no risk factors, a subset treated with RT alone showed an excellent 5-year @entity66 and @entity1349 (93.8% and 100%, respectively). Conclusion: We identified a low-risk subset of stage IIIA endometrioid @entity420 @entity1 who might be reasonable candidates for adjuvant RT alone. Further randomized studies are needed to determine which subset might benefit from combined CTRT.

title: Adjuvant Treatment after Surgery in Stage IIIA XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['Disease-free survival', 'DFS']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity1204 :: (MESH:D016889,Disease) :: ['Endometrial Adenocarcinoma']


abstract: OBJECTIVE: To investigate further the possible mechanism of @entity105 and portal invasion of @entity157 ( @entity157 ). METHODS: Samples of the @entity5 , @entity5 in the portal veins and normal liver tissues adjacent to the @entity5 were collected from 20 cases of primary @entity157 . Expression of @entity8111 ( @entity8111 ) protein was detected using Western blot. Expression of @entity8111 mRNA was detected by RT-PCR. Methylation of @entity8111 gene promoter was detected using methylation-specific PCR (MSP). RESULTS: Expression of @entity8111 protein and mRNA were obtained in all of the normal liver tissues adjacent to @entity5 . However, loss of @entity8111 protein expression was found in 5 and 36 cases respectively in the @entity5 and @entity5 cell emboli in portal veins. Expression of @entity8111 protein and mRNA in @entity5 and @entity5 emboli were significantly lower than that in the normal liver tissues. Promoter methylation of @entity8111 gene could be detected in @entity5 (7 cases) and @entity5 (9 cases) in @entity157 , while no methylation found in normal liver tissues. In all the @entity157 cases with promoter gene methylation including @entity5 and @entity5 in portal veins, 13 cases showed complete loss and 6 cases showed low expression of @entity8111 protein and mRNA. Promoter methylation of @entity8111 was noticed not related with the histological grading of @entity157 . CONCLUSIONS: There is a close relationship between loss or low expressions of @entity8111 and @entity105 and portal invasion of @entity157 . The loss and low expression of @entity8111 gene and protein were caused by methylation of the gene promoter.

title: [Relationship between XXXX expression and promoter methylation of @entity8111 gene in @entity157 ].

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'primary tumors', 'cancerous emboli', 'cancer cells emboli']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']

entities_list: @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis']

entities_list: @entity8111 :: ('7078', 'Gene') :: ['TIMP-3', 'tissue inhibitor of metalloproteinases-3']

answer: @entity8111 :: (7078,Gene) :: ['TIMP-3']


abstract: The pathogenesis of @entity6865 ( @entity6865 ) is not completely understood. However, an @entity32 , sensitization of primary somatosensory afferents, and sensitization of spinal neurons are considered to have a role in the pathogenesis of @entity6865 . The underlying pathophysiology relating the clinical picture may help to determine the pharmacotherapeutic approach for an individual @entity1 . Scintigraphy using radiolabelled human polyclonal non-specific immunoglobulin (HIG) has been recognized as a useful tool for the localization of inflammatory disorders. Thirty-six consecutive @entity6865 @entity1 associated with @entity1158 were included in this study. All the @entity1 in this study had three phases bone scan and Tc-99m HIG scintigraphy. On admission, of 36 @entity1 with positive bone scan, 30 had positive Tc-99m HIG scan. All the @entity1 were symptomatic at the time of bone scanning. On the contrary, 24 out of 36 @entity1 subsequently became asymptomatic at an 8-month re-evaluation period. Tc-99m HIG scintigraphy is a non-invasive complementary method for the determination of ongoing inflammatory reactions which also aids the clinicians to predict the response to anti-inflammatory therapy at the very early phase of @entity6865 associated with @entity1158 . This preliminary study may be a source of inspiration for further studies with larger series and longer follow-up .

title: XXXX of @entity6865 at early stages with Tc-99m HIG scintigraphy: preliminary results.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['excessive regional inflammation']

entities_list: @entity1158 :: ('MESH:D006429', 'Disease') :: ['hemiplegia']

entities_list: @entity6865 :: ('MESH:D012019', 'Disease') :: ['RSD', 'reflex sympathetic dystrophy']

answer: @entity32 :: (MESH:D007249,Disease) :: ['Determination of inflammation']


abstract: INTRODUCTION AND HYPOTHESIS: The @entity3577 ( @entity3577 ) is a vaginal approach for treating apical prolapse that provides shorter operative and recovery times and is associated with lower morbidity rates. Success rates reported for this technique are comparable with the abdominal sacrocolpopexy (SCP); however, to date, there are no prospective randomized studies comparing @entity3577 to SCP. The aim of the study was to compare the anatomical objective cure rates for the apical compartment in @entity1 undergoing either @entity3577 or SCP at 12  months' follow-up. METHODS: We performed a single-center parallel randomized controlled trial in @entity1 with severe @entity661 defined as @entity3577 Quantification (POP-Q) point C   >=    stage 3. Based on the center's previous experience, a sample size of 124 @entity1 was required to show a 20  % cure rate difference between both techniques with 80  % power and using a two-tailed 5  % level of significance. One hundred and ten @entity1 were available for analysis; 54 were allocated to abdominal SCP and 56 to @entity3577 . The primary outcome was to evaluate surgical objective success defined as POP-Q point C      stage<2. The Pelvic Floor Distress Inventory (PFDI-20), the Perceived Quality of Life Scale (P-QOL), and the @entity3577 /Urinary Incontinence Sexual Function Questionnaire (PISQ-12) questionnaires were used for subjective assessment. RESULTS: The objective success rate for apical suspension at 12  months' follow-up was 100  % for abdominal SCP and 82.5  % for @entity3577 (log-rank p 0.033). Both techniques showed a significant improvement with regards to prolapse symptoms, quality of life (QOL), and sexual function. The significant improvement in postoperative questionnaires was comparable between both surgeries at 12 months' follow-up. CONCLUSIONS: Abdominal SCP has statistically significant better anatomical results when compared with @entity3577 for correcting @entity661 at 12  months.

title: High uterosacral vault suspension vs Sacrocolpopexy for treating XXXX : a randomized controlled trial with twelve months follow-up.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity3577 :: ('MESH:D056887', 'Disease') :: ['HUVS', 'high uterosacral vault suspension', 'Pelvic Organ Prolapse']

entities_list: @entity661 :: ('MESH:D054549', 'Disease') :: ['apical defect', 'apical defects']

answer: @entity661 :: (MESH:D054549,Disease) :: ['apical defects']


abstract: BACKGROUND: The femoropopliteal arteries are subjected to considerable axial and @entity85 . The Supera helical interwoven @entity5648 stent system (IDEV Technologies, Inc/Abbott Laboratories, Inc, Webster, Tex) has good conformability and flexibility, with a very low incidence of mechanical fatigue. This study reviewed our experience with the use of Supera stents for femoropopliteal @entity731 and identified risk factors for @entity256 or @entity432 . METHODS: @entity1 with symptomatic femoropopliteal @entity731 who underwent lower limb angioplasty and Supera stent insertion were studied. All @entity1 had regular clinical follow-up and underwent a Doppler ultrasound examination at 3  months and then every 6  months, and radiography of the stents at 6, 12, 18, 24, 30, and 36  months. Patency rates were analyzed using Kaplan-Meier curves. We also evaluated the prospectively maintained cohort to identify predictors of @entity256 . RESULTS: From October 2011 to December 2014, 164 legs in 153 symptomatic @entity1 (96 male, 57 female) with @entity432 , with mean age of 76.7  years (range, 46-100  years), were included. Ninety-five @entity1 (58%) had @entity613 , nine (5%) had @entity158 , and 60 (37%) had tissue loss. Disease distribution was 64 proximal superficial femoral arteries (SFAs; 39%), 107 middle SFAs (65%), 127 distal SFAs (77%), 78 above-knee popliteal arteries (48%), and 19 below-knee popliteal arteries (12%). Lesion classification by TransAtlantic Inter-Society Consensus for the Management of @entity3657 (TASC II) A, B, C, and D was 49 (30%), 79 (48%), 31 (19%), 3 (1%), respectively. The mean lesion length was 105.6  mm (range, 3-400  mm), and more than one Supera stent was inserted in 26 @entity1 . Procedure success (residual stenosis  <30%) was achieved in 100% of procedures. The primary patency rates (>50% patency) at 6, 12, 24, and 30  months were (  standard error) 86.7%     3.1%, 81.4%     3.7%, 79.9%     4.0%, and 77     3.0%, respectively. The ankle-brachial pressure index increased from 0.57     0.15 preoperatively to 0.87     0.14 postoperatively. No stent @entity174 occurred. There were three 30-day deaths not related to the procedure or device, one major amputation 3  months after revascularization, and 29 late deaths (>30  days) of unrelated medical causes in follow-up. In-stent @entity256 was associated with younger @entity1 age and with @entity2299 , @entity66 , and stent length. CONCLUSIONS: Our midterm experience showed that the implantation of the helical interwoven @entity5648 stents in @entity1 with @entity432 is safe and effective, with encouraging patency rates and clinical results.

title: @entity256 in the use of helical interwoven XXXX stents to treat @entity432 .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['long lesion']

entities_list: @entity3657 :: ('MESH:D058729', 'Disease') :: ['Peripheral Arterial Disease']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures']

entities_list: @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia']

entities_list: @entity256 :: ('MESH:D023903', 'Disease') :: ['restenosis']

entities_list: @entity613 :: ('MESH:D007383', 'Disease') :: ['claudication']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['rest pain']

entities_list: @entity432 :: ('MESH:D001157', 'Disease') :: ['femoropopliteal occlusive disease', 'occlusion']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerotic lesions', 'atherosclerotic diseases']

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['bending deformity due to flexion at the hip and knee joints']

answer: @entity5648 :: (MESH:C013616,Chemical) :: ['nitinol']


abstract: THE PURPOSE OF THE STUDY was to evaluate the peculiarities of the clinical features, laboratory parameters and tactics of treatment in juvenile idiopatic systematic @entity625 . METHODS: A retrospective data review of 41 @entity1 (26 @entity1 and 15 @entity1 ) who underwent treatment for systemic @entity625 (according to ILAR criteria) in our institution between 1992 and 2002 was performed. RESULTS: The disease started with fever of unknown origin in all cases. In 73% of @entity1 it lasted longer than one month, in 54% fever was with twice daily spikers in the morning and in the evening. The @entity1910 during the rise of temperature appeared in 49%, in most cases (70%) there was a maculo-papular @entity1910 . Lymphadenopathy and @entity11534 were observed in 32%, @entity382 in 29%, and @entity381 in 24%. @entity625 coincided with the fever in 29% of @entity1 , in majority of cases it was progressing to a severe persistent @entity625 after the systematic phase. There was no specific laboratory findings: @entity5309 was found in 73%, @entity417 - in 80.5%, trombocytosis - in 36.6%, elevated CRP - in 63.4%, dysproteinemia - in 79% of patients. Antinuclear factors were absent in all examined @entity1 . For all @entity1 intravenous @entity1667 pulses have been administered (10-22 mg/kg/infusion). @entity617 was also continued orally (1-2 mg/kg/day). 24.4% of @entity1 required in addition immunosupressive agents such as @entity1499 , @entity500 and @entity786 . CONCLUSION: Puls-therapy of @entity1667 is a safe and sufficiently effective method of treatment in most cases of the @entity625 .

title: [Juvenile idiopathic systemic XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'girls', 'boys']

entities_list: @entity1667 :: ('MESH:D008775', 'Chemical') :: ['methylprednisolone']

entities_list: @entity625 :: ('MESH:D001168', 'Disease') :: ['systematic juvenile arthritis', 'arthritis', 'Arthritis']

entities_list: @entity500 :: ('MESH:D001379', 'Chemical') :: ['azathioprine']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity381 :: ('MESH:D013163', 'Disease') :: ['splenomegaly']

entities_list: @entity5309 :: ('MESH:C564275', 'Disease') :: ['neutrophilic leucocytosis']

entities_list: @entity382 :: ('MESH:D006529', 'Disease') :: ['hepatomegaly']

entities_list: @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']

entities_list: @entity617 :: ('MESH:D011239', 'Chemical') :: ['Prednisolone']

answer: @entity625 :: (MESH:D001168,Disease) :: ['arthritis']


abstract: OBJECTIVE: To assess the cardiopulmonary exercise testing (CPET) derived performance of @entity26 uptake and ventilation efficiency parameters, including @entity26 uptake efficiency plateau (OUEP) , @entity26 uptake efficiency slope (OUES), V  E/V  CO2 slope and lowest V  E/V  CO2, in @entity1 with end-stage @entity712 ( @entity712 ) and evaluate their clinical value on monitoring cardiac function and hemodynamic status. METHODS: A total of 26 end-stage @entity712 @entity1 considered for heart transplantation were enrolled in this study. CPET, echocardiography and invasive hemodynamic examinations with Swan-Ganz flowing balloon catheter were performed. Correlation analysis was made between @entity26 uptake and ventilation efficiency parameters from CPET and echocardiographic and hemodynamic parameters. RESULTS: OUEP and OUES showed good correlation with peak @entity26 consumption (peak @entity4962 ) (r = 0.535, P < 0.01;r = 0.840, P < 0.001). In end-stage @entity712 @entity1 , the slope of OUEP with respect to peak @entity4962 is about 32, but the slope of OUES with respect to peak @entity4962 is only about 2. The difference was 16 times. The change of OUEP was more sensitive and significant than those of OUES and peak @entity4962 (P < 0.05). OUEP, peak @entity4962 (%pred), V  E/V  CO2 slope and lowest V  E/V  CO2 were all correlated well with non-invasive hemodynamic parameters peak cardiac output (r = 0.535, P < 0.01; r = 0.652, P < 0.001; r = -0.640, P < 0.001; r = -0.606, P = 0.001 respectively) and peak cardiac index (r = 0.556, P < 0.01;r = 0.772, P < 0.001; r = -0.641, P < 0.001; r = -0.620, P < 0.001 respectively) derived from CPET, but not correlated with invasive hemodynamic parameters cardiac output and cardiac index at rest (P > 0.05). Both peak @entity4962 (%pred) and V  E/V  CO2 slope were significantly correlated with invasive hemodynamic parameters systolic pulmonary arterial pressure (r = -0.424, P < 0.05; r = 0.509, P < 0.01) and mean pulmonary arterial pressure (r = -0.479, P < 0.05; r = 0.405, P < 0.05). Peak @entity4962 (%pred) was also significantly correlated with pulmonary capillary wedge pressure (r = -0.415, P < 0.05), and V  E/V  CO2 slope was significantly correlated with pulmonary vascular resistance (r = 0.429, P < 0.05). CONCLUSIONS: The @entity26 uptake and ventilation efficiency parameters derived from CPET, including peak @entity4962 , OUEP, lowest V  E/V  CO2 and V  E/V  CO2 slope etc, are objectively monitoring and evaluating cardiac function and hemodynamic status. And they are useful for optimizing clinical management of @entity1 with end-stage @entity712 .

title: [Clinical value of cardiopulmonary exercise testing derived @entity26 uptake efficiency parameters in @entity1 with end-stage XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['chronic heart failure', 'CHF']

answer: @entity712 :: (MESH:D006333,Disease) :: ['chronic heart failure']


abstract: From January 1978 to June 1979, 29 selected, previously untreated @entity1 with unfavorable histology of @entity1893 (12 DPDL, 7 @entity3918 , 9 DH and 1 DU) were submitted to the combination chemotherapy @entity3726 ( @entity786 , 750 mg/m2 i.v. on day 1; @entity632 , 50 mg/m2 i.v. on day 1; @entity1891 , 1.4 mg/m2 i.v. on day 1, and @entity229 , 100 mg p.o. on day 1 through 5) every 21 days. Eighteen @entity1 were in early stage (I or II) and 11 of them were also submitted to involved field radiotherapy (60Co), immediately before (stage I) or during (stage II) the chemotherapy, with a mean dosage of 4,500 rad. The remaining 11 @entity1 were in advanced stage (III or IV) of disease and were treated with chemotherapy alone. We obtained 20 complete remissions (68%), 8 partial remissions (28%) and 1 no response (4%) to therapy. Sixteen of 18 @entity1 (89%) in early stages and 4 of 11 @entity1 (36%) in advanced stages achieved a complete remission. The @entity236 of the chemotherapy was moderate. @entity390 , @entity391 and @entity294 were frequent but well controlled by the support therapy. The actuarial survival rate of @entity1 , after 18 months of follow-up, is 41% (40% in complete remission). The @entity1 who achieved a complete remission are alive and 65% of them still relapse free. We believe that the combination chemotherapy @entity3726 improves the complete remission rate as well as the survival of @entity1 with unfavorable histology of @entity1893 .

title: Combination chemotherapy with @entity786 , @entity632 , @entity1891 and @entity229 ( XXXX ) for @entity1893 with unfavorable histology: preliminary results.

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['adriamycin']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity236 :: ('MESH:D001855', 'Disease') :: ['bone marrow toxicity']

entities_list: @entity1891 :: ('MESH:D014750', 'Chemical') :: ['vincristine']

entities_list: @entity1893 :: ('MESH:D008228', 'Disease') :: ["non-Hodgkin's lymphomas"]

answer: @entity3726 :: (1649,Gene) :: ['CHOP']


abstract: As a cornerstone of the innate immune response, neutrophils are the archetypical phagocytic cell; they actively seek out, ingest, and destroy pathogenic microorganisms. To achieve this essential role in host defense, neutrophils deploy a potent antimicrobial arsenal that includes oxidants, proteinases, and antimicrobial peptides. Importantly, oxidants produced by neutrophils, referred to in this article as reactive @entity26 (ROS) and reactive @entity1568 ( @entity16631 ) species, have a dual function. On one hand they function as potent antimicrobial agents by virtue of their ability to kill microbial pathogens directly. On the other hand, they participate as signaling molecules that regulate diverse physiological signaling pathways in neutrophils. In the latter role, ROS and @entity16631 serve as modulators of protein and lipid kinases and phosphatases, membrane receptors, ion channels, and transcription factors, including NF-kappaB. The latter regulates expression of key cytokines and chemokines that further modulate the inflammatory response. During the inflammatory response, ROS and @entity16631 modulate phagocytosis, secretion, gene expression, and apoptosis. Under pathological circumstances such as @entity647 and @entity295 , excess production of ROS may influence vicinal cells such as endothelium or epithelium, contributing to inflammatory tissue injury. A better understanding of these pathways will help identify novel targets for amelioration of the untoward effects of @entity32 .

title: Reactive XXXX and @entity1568 species as signaling molecules regulating neutrophil function.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity1568 :: ('MESH:D009584', 'Chemical') :: ['nitrogen']

entities_list: @entity647 :: ('MESH:D055371', 'Disease') :: ['acute lung injury']

answer: @entity26 :: (MESH:D010100,Chemical) :: ['oxygen']


abstract: OBJECTIVE: To investigate @entity6864 ( @entity6864 ) expressions in @entity1 with actively proliferating @entity631 such as type IV @entity1988 ( @entity1988 ) and cellular crescentic @entity631 (RPGN). METHODS: All @entity1 were divided into 4 groups as follows: RPGN (17 cases); @entity1988 (15 cases); mild mesangial proliferative IgA @entity8 ( @entity6994 , 7 cases) and @entity1987 ( @entity1987 , 10 cases). Clinical parameters, immunohisto-chemistry stain and in situ hybridization of renal biopsy specimens were performed. RESULTS: Clinically, @entity644 and hematouria were increased and Ccr were decreased in @entity1988 and RPGN @entity1 , and increased ESR and decreased @entity4417 were found in group @entity1988 . Active index of renal specimens were significantly higher in @entity1988 and RPGN groups than in @entity6994 and @entity1987 groups. Renal specimens of @entity1987 @entity1 showed no positive @entity6864 staining in all sections; little immunoreactivity was detected in sections of glomerular, tubular and interstitial cells from @entity6994 @entity1 . Glomerular positive staining of @entity6864 in renal sections in @entity1988 and RPGN @entity1 [(3.3 +/- 1.8) and (2.8 +/- 1.2) cells per section of glomerulus, respectively] were significantly increased compared with that in @entity6994 @entity1 [(0.7 +/- 0.5) cells per section of glomerulus]. Similarly, tubular positive staining of @entity6864 in @entity1988 and RPGN @entity1 (27.38 +/- 12.46, 23.36 +/- 10.55) were also elevated compared with that in @entity6994 and @entity1987 @entity1 (6.51 +/- 3.49, 1.72 +/- 0.31). The relevance assay results showed positive relationship between active index and glomerular or tubular @entity6864 immunohisto-chemistry staining cell numbers (0.478, P < 0.01; 0.513, P < 0.01). Tubular @entity6864 mRNA expression in @entity1988 and RPGN @entity1 was upregulated by in situ hybridization. CONCLUSION: Our results demonstrate in vivo that @entity6864 expression was increased in active @entity631 @entity1 accompanied with clinical and pathological active @entity32 . These data suggest that increase of @entity6864 expression in renal cells may play an important role in response to inflammatory stress.

title: [ @entity6864 expression in the kidney of actively proliferating XXXX ].

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['nephropathy']

entities_list: @entity1987 :: ('MESH:D009402', 'Disease') :: ['MCD', 'minimal change disease']

entities_list: @entity1988 :: ('MESH:D008181', 'Disease') :: ['LN', 'LN type IV', 'lupus nephritis']

entities_list: @entity631 :: ('MESH:D005921', 'Disease') :: ['glomerulonephritis']

entities_list: @entity6864 :: ('5468', 'Gene') :: ['peroxisome proliferator-activated receptor gamma', 'PPAR-gamma']

answer: @entity631 :: (MESH:D005921,Disease) :: ['glomerulonephritis']


abstract: OBJECTIVE: To determine the comparative efficacy and safety of antipsychotics for youth with early-onset @entity161 using network meta-analytic methods combining direct and indirect trial data. METHOD: The authors systematically searched MEDLINE, the Cochrane Library, and clinicaltrials.gov and selected randomized controlled trials allocating youth with @entity161 spectrum disorders to a (non- @entity1088 ) antipsychotic versus placebo or another antipsychotic. Major efficacy outcomes were Positive and Negative Syndrome Scale (PANSS) total and positive symptoms. Major safety outcomes were weight, plasma @entity412 levels, @entity21 , @entity2146 , and all-cause discontinuation. Sixteen additional outcomes were analyzed. A random-effects arm-based network meta-analysis was applied, and consistency was assessed by pairwise meta-analysis. Confidence in PANSS total estimates was assessed by applying the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: Twelve 6- to 12-week trials (N  = 2,158; 8-19 years old; 61% @entity1 ) involving 8 antipsychotics ( @entity1770 , @entity15177 , @entity7302 , @entity1090 , @entity1089 , @entity1037 , @entity16680 , and @entity1280 ) were analyzed. PANSS total symptom change was comparable among antipsychotics (low- to moderate-quality evidence), except @entity1280 (very low- to low-quality evidence), and all  antipsychotics were superior to placebo (low- to high-quality evidence), except @entity1280 and @entity15177 (low- to moderate-quality evidence). PANSS positive changes and additional efficacy outcomes were comparable among antipsychotics. @entity1017 was primarily associated with @entity1037 ; @entity21 and @entity2146 were associated with @entity16680 ; and prolactin increased with @entity1090 , @entity7302 , and @entity1037 . Serious adverse events, discontinuation of treatment, sedation, @entity22 , or change in @entity1674 did not differ among antipsychotics. CONCLUSION: This network meta-analysis showed comparable efficacy among antipsychotics for early-onset @entity161 , except that efficacy appeared inferior for @entity1280 and unclear for @entity15177 . Adverse reaction profiles varied substantially among the investigated antipsychotics and were largely consistent with prior findings in adults. Protocol registration information-Antipsychotic Treatment for @entity1 With @entity161 Spectrum Disorders: Network Meta-Analysis of Randomised Trials; https://www.crd.york.ac.uk/PROSPERO/; CRD42013006676.

title: Acute Antipsychotic Treatment of @entity1 and Adolescents With XXXX -Spectrum Disorders: A Systematic Review and Network Meta-Analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['Children', 'boys']

entities_list: @entity1088 :: ('MESH:D003024', 'Chemical') :: ['clozapine']

entities_list: @entity15177 :: ('MESH:C522667', 'Chemical') :: ['asenapine']

entities_list: @entity7302 :: ('MESH:C079150', 'Chemical') :: ['paliperidone']

entities_list: @entity16680 :: ('MESH:D008972', 'Chemical') :: ['molindone']

entities_list: @entity1280 :: ('MESH:C092292', 'Chemical') :: ['ziprasidone']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity22 :: ('MESH:D007319', 'Disease') :: ['insomnia']

entities_list: @entity412 :: ('CHEBI:17855', 'Chemical') :: ['triglyceride']

entities_list: @entity2146 :: ('MESH:D011595', 'Disease') :: ['akathisia']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia', 'Schizophrenia']

entities_list: @entity1017 :: ('MESH:D015430', 'Disease') :: ['Weight gain']

entities_list: @entity21 :: ('MESH:D001480', 'Disease') :: ['extrapyramidal symptoms']

entities_list: @entity1037 :: ('MESH:C076029', 'Chemical') :: ['olanzapine']

entities_list: @entity1770 :: ('MESH:C094645', 'Chemical') :: ['aripiprazole']

entities_list: @entity1089 :: ('MESH:C069541', 'Chemical') :: ['quetiapine']

entities_list: @entity1090 :: ('MESH:D018967', 'Chemical') :: ['risperidone']

answer: @entity161 :: (MESH:D012559,Disease) :: ['Schizophrenia']


abstract: The @entity876 homologue @entity4206 produces six different isoforms that are important in development of epithelial tissues and @entity213 ( @entity213 ). In @entity213 , the expression of @entity4206 isoforms is highly complex, with over-expression of DeltaNp63 and p63beta isoforms in many @entity5 . To date, little is known about the functions of different DeltaNp63 isoforms and elucidating the distinctive properties of DeltaNp63 isoforms will help to clarify how they influence @entity5 biology. By gene expression profiling of @entity213 cells over-expressing the DeltaNp63 isoforms we identified different effects of the three isoforms, with DeltaNp63beta being more effective at gene induction than DeltaNp63alpha and DeltaNp63gamma, whereas DeltaNp63gamma was most effective at repressing gene expression. Thus, @entity5 expressing even low levels of DeltaNp63beta or DeltaNp63gamma may have distinct clinicopathological characteristics important for @entity3 and therapeutic response. Induction of @entity3840 ( @entity3840 ) was shown by each isoform and data were confirmed by independent quantitative RT-PCR and western blotting. No direct binding of DeltaNp63 to the @entity3840 promoter could be seen, neither could any evidence for @entity3840 induction as a consequence of activated NF-kappaB pathway responses be found. As @entity3840 is known to inhibit radiotherapy responses in @entity213 @entity1 , data indicate an additional mechanism through which DeltaNp63 acts to promote cell survival and influence therapeutic response of @entity213 . MIAME-compliant data have been deposited in the MIAME Express database (Accession No. E-MEXP-1842).

title: DeltaNp63 isoforms differentially regulate gene expression in squamous cell carcinoma: identification of XXXX as a novel @entity4206 target.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

entities_list: @entity213 :: ('MESH:C535575', 'Disease') :: ['squamous cell carcinoma of the head and neck', 'SCCHN']

answer: @entity3840 :: (5743,Gene) :: ['Cox-2']


abstract: UNASSIGNED: 8046 Background: In a previous Phase I study, @entity1037 ( @entity1037 ) was demonstrated to be a safe and effective agent for the prevention of delayed @entity391 in chemotherapy na  ve @entity5 @entity1 receiving @entity786 , @entity632 , and/or @entity900 . METHODS: Using the maximum tolerated dose of @entity1037 in the Phase I trial, a Phase II trial was performed for the prevention of @entity1209 in chemotherapy naive @entity1 . The regimen was 5mg/day of oral @entity1037 on the two days prior to chemotherapy, 10mg of @entity1037 on the day of chemotherapy, day 1, (added to intravenous granisetron, 10 mcg/kg, and @entity619 20 mg) and 10 mg/day on days 2-4 after chemotherapy (added to @entity619 , 8 mg p.o. BID, days 2,3, and 4 mg p.o. BID, day 4). Thirty @entity1 (median age 58.5 yrs, range 25-84; 23 females; ECOG PS 0,1) consented to the protocol and all were evaluable. RESULTS: Complete response (CR) (no @entity391 , no rescue) was 100% for the acute period (24 hours post chemotherapy) and 80% for the delayed period (days 2-5 post chemotherapy) in 10 @entity1 receiving highly emetogenic chemotherapy (HEC) ( @entity900 , >=  70 mg/m2). CR was also 100% for the acute period and 85% for the delayed period in 20 @entity1 receiving @entity7730 ( @entity7730 ) ( @entity632 , >=  50 mg/m2). @entity390 was well controlled in the @entity1 receiving HEC with no @entity1 having more than minimal @entity390 (<= 2 on scale of 0-10, M.D. Anderson Symptom Inventory, MDASI) in the acute or delayed periods. @entity390 was also well controlled in @entity1 receiving @entity7730 with minimal or no @entity390 in 85% of @entity1 in the acute period and 70% in the delayed period. There were no Grade 3 or 4 @entity137 and no significant @entity158 , @entity1295 , disturbed sleep, memory changes, @entity1353 , @entity1277 , drowsiness, @entity2133 , mood changes or @entity2146 experienced by the @entity1 . CR and control of @entity390 in subsequent cycles of chemotherapy (25 @entity1 , cycle 2; 25 @entity1 , cycle 3; 21 @entity1 , cycle 4) were equal to or greater than cycle 1. CONCLUSIONS: @entity1037 is safe and highly effective in controlling acute and delayed @entity1209 in @entity1 receiving HEC and @entity7730 . No significant financial relationships to disclose.

title: A phase II trial of @entity1037 for the prevention of @entity1209 ( XXXX ).

entities_list: @entity1 :: ('9606', 'Species') :: ['patient', 'patients']

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities']

entities_list: @entity390 :: ('MESH:D009325', 'Disease') :: ['Nausea', 'nausea']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity1277 :: ('MESH:D001068', 'Disease') :: ['lack of appetite']

entities_list: @entity2146 :: ('MESH:D011595', 'Disease') :: ['restlessness']

entities_list: @entity7730 :: ('MESH:D064146', 'Disease') :: ['moderately emetogenic chemotherapy', 'MEC']

entities_list: @entity1037 :: ('MESH:C076029', 'Chemical') :: ['olanzapine', 'Zyprexa', 'Olanzapine']

answer: @entity1209 :: (MESH:D020250,Disease) :: ['CINV']


abstract: We examined the effect of @entity50433 (SAC), a water-soluble garlic constituent, on cytokeratin expression, a sensitive and specific marker for differentiation status during @entity3653 ( @entity106 )-induced @entity14705 ( @entity14705 ) @entity105 in male @entity329 . Hamsters were divided into four groups of six animals each. Animals in group 1 were painted with a 0.5% solution of @entity106 in liquid paraffin on the right buccal pouches three times a week for 14 weeks. Group 2 animals were painted with @entity106 as in group I, and in addition they received orally 200 mg/kg of SAC on days alternate to @entity106 application. Group 3 animals received SAC as in group 2. Group 4 animals received neither @entity106 nor SAC and served as the control. The hamsters were killed after an experimental period of 14 weeks. Cytokeratin expression was detected by Western blot analysis using monoclonal antibodies AE1 and AE3. In @entity106 -induced @entity5 , the decreased expression of high molecular weight cytokeratins of molecular mass between 55-70 kDa was observed. Administration of SAC (200 mg/kg) to animals painted with @entity106 suppressed the incidence of @entity106 -induced @entity189 and was associated with restoration of normal cytokeratin expression. The results of the present study suggest that inhibition of @entity14705 tumorigenesis by SAC may be due to its regulatory effects on differentiation, @entity5 invasiveness, and its ability to migrate and form @entity3 .

title: Altered cytokeratin expression during chemoprevention of @entity14705 @entity105 by XXXX .

entities_list: @entity3653 :: ('CHEBI:254496', 'Chemical') :: ['7,12-dimethylbenz[a]anthracene']

entities_list: @entity14705 :: ('MESH:D007967', 'Disease') :: ['hamster buccal pouch', 'HBP']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'HBP tumors']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas']

entities_list: @entity50433 :: ('MESH:C065299', 'Chemical') :: ['S-allylcysteine']

entities_list: @entity329 :: ('10036', 'Species') :: ['Syrian hamsters']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis']

answer: @entity50433 :: (MESH:C065299,Chemical) :: ['S-allylcysteine']


abstract: BACKGROUND: Contrast enhanced magnetic resonance angiography (MRA) is generally performed during a long breath-hold (BH), limiting its utility in @entity1 and small @entity1 . This study proposes a free-breathing (FB) time resolved MRA (TRA) technique for use in pediatric and adult @entity299 ( @entity299 ). METHODS: A TRA sequence was developed by combining spiral trajectories with sensitivity encoding (SENSE, x4 kx-ky and x2 kz) and partial Fourier (75% in kz). As no temporal data sharing is used, an independent 3D data set was acquired every ~1.3s, with acceptable spatial resolution (~2.3x2.3x2.3mm). The technique was tested during FB over 50 consecutive volumes. Conventional BH-MRA and FB-TRA data was acquired in 45 adults and @entity1 with @entity299 . We calculated quantitative image quality for both sequences. Diagnostic accuracy was assessed in all @entity1 from both sequences. Additionally, vessel measurements were made at the sinotubular junction (N   =   43), proximal descending aorta (N   =   43), descending aorta at the level of the diaphragm (N   =   43), @entity358 (N   =   35), @entity358 (N   =   35) and the right pulmonary artery (N   =   35). Intra and inter observer variability was assessed in a subset of 10 @entity1 . RESULTS: BH-MRA had significantly higher homogeneity in non-contrast enhancing tissue (coefficient of variance, P   <0.0001), signal-to-noise ratio (P   <0.0001), contrast-to-noise ratio (P   <0.0001) and relative contrast (P   =   0.02) compared to the FB-TRA images. However, homogeneity in the vessels was similar in both techniques (P   =   0.52) and edge sharpness was significantly (P   <0.0001) higher in FB-TRA compared to BH-MRA. BH-MRA provided overall diagnostic accuracy of 82%, and FB-TRA of 87%, with no statistical difference between the two sequences (P   =   0.77). Vessel diameter measurements showed excellent agreement between the two techniques (r   =   0.98, P   <0.05), with no bias (0.0mm, P   =   0.71), and clinically acceptable limits of agreement (-2.7 to +2.8mm). Inter and intra observer reproducibility showed good agreement of vessel diameters (r>0.988, P<0.0001), with negligible biases (between -0.2 and +0.1mm) and small limits of agreement (between -2.4 and +2.5mm). CONCLUSIONS: We have described a FB-TRA technique that is shown to enable accurate diagnosis and vessel measures compared to conventional BH-MRA. This simplifies the MRA technique and will enable angiography to be performed in @entity1 and adults whom find breath-holding difficult.

title: Free breathing contrast-enhanced time-resolved magnetic resonance angiography in pediatric and adult XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'infants']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['main pulmonary artery', 'left pulmonary artery']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['CHD', 'congenital heart disease']

answer: @entity299 :: (MESH:D006331,Disease) :: ['congenital heart disease']


abstract: The @entity137 of most drugs is associated with their enzymatic conversion to toxic metabolites. Bioactivation reactions occur in a range of cellular organs and organelles, including mitochondria. We have investigated different effects (i.e. growth inhibition, mortality and genotoxicity) of @entity632 , @entity1259 and @entity2664 on the D7 strain of @entity375 and on its petite (rho degrees ) @entity1576 mutant at various cellular concentrations of cytochrome P450 and @entity2041 ( @entity2197 ). The data confirmed the importance of @entity26 production for @entity632 @entity137 . The complete absence, or a very low level, of cytochrome oxidase subunit IV conferred some resistance to @entity632 . Low @entity2197 levels decreased resistance to @entity632 in both strains, suggesting that @entity1432 depletion could potentiate membrane lipid peroxidation. @entity632 induction of petite colonies suggests that the drug is able to select rather than induce @entity1576 mutants. @entity1259 induced levels of @entity137 similar to those of @entity632 . The effects did not appear to be significantly dependent on mitochondrial function or @entity2197 levels, whereas cells were strongly protected by cytochrome P450. @entity2197 did not induce an evident alteration. Neither were genotoxic effects induced. @entity2664 had reduced levels of both growth inhibition and @entity137 in comparison to @entity8253 and induced convertants, revertants and aberrants. All the effects considered were amplified at high cytochrome P450 cellular concentrations, although the drug was also shown to act without previous metabolism via cytochrome P450. Anthracenedione effectiveness was increased by metabolism via cytochrome P450 and partially reduced by @entity2197 . However, further mechanisms were suggested, which might implicate mitochondrial function and/or production of electrophilic cytotoxic and/or genotoxic intermediates by means of @entity2197 conjugation. The biological effectiveness of @entity632 , @entity1259 and @entity2664 on @entity375 was shown to be strictly dependent on cell-specific physiological/biochemical conditions, such as a functional respiratory chain and levels of cytochrome P450 and @entity2197 .

title: @entity375 as an eukaryotic cell model to assess XXXX and genotoxicity of three anticancer anthraquinones.

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin', 'Doxorubicin']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'cytotoxicity']

entities_list: @entity8253 :: ('MESH:D018943', 'Chemical') :: ['anthracyclines']

entities_list: @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen']

entities_list: @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone', 'Mitoxantrone']

entities_list: @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin', 'Epirubicin']

entities_list: @entity2041 :: ('MESH:D005978', 'Chemical') :: ['glutathione']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory-deficient']

entities_list: @entity375 :: ('4932', 'Species') :: ['S.cerevisiae', 'Saccharomyces cerevisiae']

answer: @entity137 :: (MESH:D064420,Disease) :: ['cytotoxicity']


abstract: BACKGROUND: Some @entity1 with @entity631 ( @entity631 ) develop @entity644 , @entity101 and different degrees of CKD, besides the persistent microhaematuria characteristic of the disease. Little is known about factors associated with this unfavourable outcome. METHODS: We reviewed clinical, pathological and radiological features of 32 @entity1 with biopsy-proven @entity631 . @entity1 were divided in two groups: those with persistent normal kidney function and negative or minimal @entity644 (n = 16) and those with persistent @entity644 >0.5 g/day (n = 16). RESULTS: @entity1 with @entity644 had a worse kidney function at baseline than those with negative @entity644 . Global or segmental @entity631 , together with interstitial @entity82 , was found in 37% of @entity1 with @entity644 . All proteinuric @entity1 were treated with @entity916 -angiotensin system blockers. At the end of follow-up (198 months in proteinuric @entity1 and 210 months in @entity1 with negative @entity644 ) the prevalence of @entity101 was 68% in proteinuric @entity1 (12% at baseline), compared with 12 and 6%, respectively, in @entity3257 @entity1 . A slow decline of renal function was observed in proteinuric @entity1 , although no @entity1 developed @entity454 . Ultrasound studies showed bilateral @entity8 in nine @entity1 (56%) with @entity644 . Cysts were bilateral and countless in six @entity1 , and bilateral but with a limited number of cysts in the three remaining @entity1 . No cysts were found in @entity1 with negative @entity644 . CONCLUSIONS: Some @entity1 with @entity631 develop @entity101 , @entity644 and CKD. Multiple bilateral @entity8 were found in a majority (56%) of these @entity1 . Further studies are needed to investigate the pathogenesis and the influence on long-term outcome of this @entity631 -associated multiple @entity8 .

title: @entity8 in @entity631 with XXXX and kidney function impairment.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient']

entities_list: @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['kidney cysts']

entities_list: @entity82 :: ('MESH:D005355', 'Disease') :: ['fibrosis']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity631 :: ('MESH:D005921', 'Disease') :: ['thin basement membrane disease', 'TBMD', 'glomerulosclerosis']

entities_list: @entity3257 :: ('MESH:C580335', 'Disease') :: ['non-proteinuric']

entities_list: @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage kidney disease']

answer: @entity644 :: (MESH:D011507,Disease) :: ['proteinuria']


abstract: OBJECTIVE: To investigate the differential effects of dietary diversity (DD) and maternal characteristics on @entity1 linear growth at different points of the conditional distribution of @entity1240 ( @entity1240 ) in sub-Saharan Africa. DESIGN: Secondary analysis of data from nationally representative cross-sectional samples of singleton @entity1 aged 0-59 months, born to mothers aged 15-49 years. The outcome variable was @entity1 @entity1240 . Quantile regression was used to perform the multivariate analysis. SETTING: The most recent Demographic and Health Surveys from Ghana, Nigeria, Kenya, Mozambique and Democratic Republic of Congo (DRC). SUBJECTS: The present analysis was restricted to @entity1 aged 6-59 months (n 31 604). RESULTS: DD was associated positively with @entity1240 in the first four quantiles (5th, 10th, 25th and 50th) and the highest quantile (90th) in Nigeria. The largest effect occurred at the very bottom (5th quantile) and the very top (90th quantile) of the conditional @entity1240 distribution. In DRC, DD was significantly and positively associated with @entity1240 in the two lower quantiles (5th, 10th). The largest effects of maternal education occurred at the lower end of the conditional @entity1240 distribution in Ghana, Nigeria and DRC. Maternal BMI and height also had positive effects on @entity1240 at different points of the conditional distribution of @entity1240 . CONCLUSIONS: Our analysis shows that the association between DD and maternal factors and @entity1240 differs along the conditional @entity1240 distribution. Intervention measures need to take into account the heterogeneous effect of the determinants of @entity1 nutritional status along the different percentiles of the @entity1240 distribution.

title: Differential effects of dietary diversity and maternal characteristics on linear growth of XXXX aged 6-59 months in sub-Saharan Africa: a multi-country analysis.

entities_list: @entity1 :: ('9606', 'Species') :: ['child', 'children']

entities_list: @entity1240 :: ('MESH:D019588', 'Disease') :: ['HAZ', 'height-for-age Z-score']

answer: @entity1 :: (9606,Species) :: ['children']


abstract: BACKGROUND: Receptor @entity4149 kinases (RTKs) play crucial roles in numerous @entity5 cell processes including cell survival, proliferation, and migration. @entity16629 MAPK kinases are very important for @entity5 survival and development. @entity2867 ( @entity2867 ) is a deadly type of @entity259 and there are no very effective systemic treatment strategies for @entity2867 so far. Also, @entity2867 can easily become resistant to therapy of traditional therapeutic drugs for @entity2867 , such as @entity632 . Drug combination treatment could be a promising therapeutic strategy for @entity2867 , especially for drug resistant @entity2867 . METHODS: We explored the combination effect between a @entity16629 inhibitor @entity37257 and a multi-targeted RTK inhibitor @entity2240 in @entity632 resistant @entity2867 cells using cell viability assay, cell migration assay, nuclei morphology and @entity522 activity analysis, as well as in vivo @entity5 growth assay. RESULTS: There is a significant additive effect between @entity37257 and @entity2240 in reducing viability, increasing apoptosis, and suppressing migration of @entity632 -resistant @entity2867 cells. Importantly, combination of @entity37257 and @entity2240 induced significant additive suppression of in vivo @entity632 -resistant @entity2867 @entity5 growth. CONCLUSIONS: Our results suggest that the combination of @entity16629 inhibitor and RTK inhibitor is promising for treatment of @entity2867 especially @entity632 -resistant @entity2867 . The combination might not only enhance the anti- @entity5 efficacy, but also reduce the side effects and overcome drug resistance developed in @entity2867 treatment. All these might provide useful information for clinical therapeutics of @entity2867 .

title: Combination of @entity37257 and XXXX leads to an additive anti- @entity5 effect in @entity632 resistant @entity259 cells.

entities_list: @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin']

entities_list: @entity2240 :: ('MESH:C473478', 'Chemical') :: ['Sunitinib Malate']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid cancer']

entities_list: @entity2867 :: ('MESH:D065646', 'Disease') :: ['ATC', 'Anaplastic thyroid carcinoma']

answer: @entity2240 :: (MESH:C473478,Chemical) :: ['Sunitinib Malate']


abstract: UNASSIGNED: 7558 Background: Whole Brain Radiotherapy (WBRT) and systemic chemotherapy remain the mainstays of therapy for metastatic @entity320 not amenable to surgical resection. The proven efficacy of @entity2903 ( @entity2904 ) on both primary and metastatic @entity1313 prompted us to conduct this phase II study to determine the activity of @entity2904 treatment following WBRT in @entity1 (pts) with untreated brain @entity3 from @entity320 . METHODS: Single CNS @entity3 eligible to surgery and/or stereotactic radiosurgery, prior treatment for CNS @entity3 , severe medical conditions interfering with oral intake were the main exclusion criteria. Treatment plan included : WBRT at 6 Gy/day administered over a two-week period (on wks 1-2) for 4 fractions (total dose 24 Gy), followed, on wk 7, by orally @entity2904 at a dose of 150 mg/m(2)/day * 5 days every 4 wks, for up to 6 cycles. Pts who received at least one cycle of @entity2904 were assessable for response. RESULTS: Twenty-seven pts (15 M and 12 F, ages 26 to 72) entered the study. Number of CNS @entity3 was 1 (6 pts), >=  2 (21 pts, range 2-6). In most of the pts (85%), extracerebral disease sites were detected (range, 1-5). Ten pts (37%), after received RT as initial management, dropped out due to @entity204 or general physical impairment. Among 17 pts who started @entity2904 chemotherapy, 2 pts lost to follow-up, 6 pts prematurely withdrew from study due to cerebral progression, 9 pts received >=  3 cycles, and 5 pts completed treatment plan. The median number of @entity2904 cycles/pt was 3 (range, 1-6). Among 15 evaluable pts, 5 stabilization of disease and 3 partial responses on cerebral sites were achieved. The median survivals of pts who received RT alone or RT plus @entity2904 , were 35 days (range, 5-80 days) and 180 days (range, 56-360 days), respectively. Treatment related @entity137 was minimal with only two dose-modifications required due to @entity882 and @entity391 . CONCLUSIONS: Compared with historical data, these preliminary results show that some of the pts who received complete treatment plan could achieve @entity1162 control and survival. Final data analysis will be presented. No significant financial relationships to disclose.

title: Radiotherapy followed by @entity2903 in the treatment of @entity1 with XXXX metastatic to the brain: An Italian multicentre study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumors']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastases']

entities_list: @entity2903 :: ('MESH:C047246', 'Chemical') :: ['Temozolomide']

entities_list: @entity1162 :: ('MESH:D008133', 'Disease') :: ['prolonged disease']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'brain melanoma']

answer: @entity320 :: (MESH:D008545,Disease) :: ['melanoma']